Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with CYP450 2C9 inhibitors may increase the plasma concentration of meloxicam, which has been shown to be primarily metabolized by this isoenzyme. In a study of healthy volunteers, voriconazole, a weak CYP450 2C9 inhibitor increased the systemic exposure of meloxicam by 47% and prolonged the average meloxicam half-life by 51%.

MANAGEMENT: The potential for an interaction should be considered during concomitant use. If coadministration is required, monitor patients for NSAID-related side effects and toxicity including gastrointestinal bleeding or perforation. Dose adjustment of meloxicam may be warranted.

Consumer information for this interaction is not currently available.

MONITOR: Smoking and alcohol consumption during therapy with vadadustat may increase the risk of gastrointestinal erosions. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, have been reported during vadadustat clinical trials. Patients with a history of gastrointestinal erosion, peptic ulcer disease, and current tobacco smokers and alcohol drinkers may be at higher risk of gastrointestinal injury.

MANAGEMENT: Caution is advised if vadadustat is prescribed to current tobacco smokers or alcohol drinkers. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, hematemesis, trouble swallowing, chest or throat pain, and/or black, tarry stools.